HighTide Therapeutics Sets 31 Aug 2026 Board Meeting to Approve Interim Results
Bulletin Express
Aug 14
HighTide Therapeutics, Inc. has scheduled a board meeting for Monday, 31 August 2026. According to the company’s announcement, the agenda includes consideration and approval of the interim financial results for the six months ended 30 June 2026 and their subsequent publication, along with other corporate matters.
The notice, issued by Executive Director and Chief Executive Officer Dr. Liu Liping on 14 August 2026, confirms the current composition of the Board: two executive directors (Dr. Liu Liping and Ms. Yu Meng), three non-executive directors (Dr. Zhu Xun, Mr. Ma Lixiong and Mr. Jiang Feng), and three independent non-executive directors (Dr. Li Jin, Mr. Hung Tak Wai and Mr. Chen Mingyu).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.